Eldecalcitol, a vitamin D analog, reduces bone turnover and increases trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

Bone

Volumn 57, Issue 1, 2013, Pages 116-122

  Smith, Susan Y ^a   Doyle, Nancy ^a   Boyer, Marilyne ^a   Chouinard, Luc ^a   Saito, Hitoshi ^b  

^a CHARLES RIVER LABORATORIES   (United States)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bone histomorphometry; Bone marker; Bone mineral density; Bone strength; Osteoporosis; Vitamin D

Indexed keywords

ELDECALCITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; BRAIN CORTEX; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FEMUR NECK; LUMBAR VERTEBRA; MACACA FASCICULARIS; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; SINGLE DRUG DOSE; TRABECULAR BONE;

BONE HISTOMORPHOMETRY; BONE MARKER; BONE MINERAL DENSITY; BONE STRENGTH; OSTEOPOROSIS; VITAMIN D;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; FEMALE; MACACA FASCICULARIS; OSTEOGENESIS; OVARIECTOMY; VITAMIN D;

EID: 84882801579     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.06.005     Document Type: Article

References (18)

1. Uchiyama Y., Higuchi Y., Takeda S., Masaki T., Shira-Ishi A., Sato K., et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002, 30(4):582-588.
2. Sakai S., Endo K., Takeda S., Mihara M., Shiraishi A. Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength. Bone 2012, 50(5):1054-1063.
3. Harada S., Mizoguchi T., Kobayashi Y., Nakamichi Y., Takeda S., Sakai S., et al. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 2012, 27(2):461-473.
4. Saito H., Harada S., Takahashi F. Active vitamin D3 inhibits bone resorption in vivo. Med Sci Dig 2011, 37(3):111-115. [ISSN:1347-4340].
5. Hatakeyama S., Nagashima S., Imai N., Takahashi K., Ishihara J., Sugita A., et al. Synthesis and biological evaluation of a 3-positon epimer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71). J Steroid Biochem Mol Biol 2007, 103(3-5):222-226.
6. Furuichi T., Kawata S., Asoh Y., Kumaki K., Ohyama Y. Differential time course of induction of 1alpha,25-dihydroxyvitamin D3-24-hydroxylase mRNA expression in rats by 1alpha,25-dihydroxyvitamin D3 and its analogs. Life Sci 1998, 62(5):453-459.
7. Brown A.J., Ritter C.S. The vitamin D analog 1α,25-dihydroxy-2β-(3-hydroxypropyloxy) vitamin D(3) (eldecalcitol) is a potent regulator of calcium and phosphate metabolism. Calcif Tissue Int 2011, 89(5):372-378.
8. Matsumoto T., Endo I. Eldecalcitol for the treatment of osteoporosis. Drugs Today (Barc) 2012, 48(3):189-196.
9. Matsumoto T., Miki T., Hagino H., Sugimoto T., Okamoto S., Hirota T., et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2005, 90(9):5031-5036.
10. Matsumoto T., Ito M., Hayashi Y., Hirota T., Tanigawara Y., Sone T., et al. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures-a randomized, active comparator, double-blind study. Bone 2011, 49(4):605-612.
11. Brommage R. Perspectives on using nonhuman primates to understand the etiology and treatment of postmenopausal osteoporosis. J Musculoskelet Neuronal Interact 2001, 1(4):307-325.
12. Jerome C.P., Peterson P.E. Nonhuman primate models in skeletal research. Bone 2001, 29:1-6.
13. Smith S.Y., Jolette J., Turner C.H. Skeletal health: primate model of postmenopausal osteoporosis. Am J Primatol 2009, 71(9):752-765.
14. Adams J.S., Chen H., Chun R.F., Nguyen L., Wu S., Ren S.Y., et al. Novel regulators of vitamin D action and metabolism: lessons learned at the Los Angeles zoo. J Cell Biochem 2003, 88(2):308-314.
15. Smith S.Y., Recker R.R., Hannan M., Müller R., Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003, 32(1):45-55.
16. Hotchkiss C.E., Stavisky R., Nowak J., Brommage R., Lees C.J., Kaplan J. Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys. Bone 2001, 29(1):7-15.
17. Lees C.J., Register T.C., Turner C.H., Wang T., Stancill M., Jerome C.P. Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 2002, 9(5):320-328.
18. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2(6):595-610.